Research Updates

Back to feed
Clinical trials
Registered study

High importance

Oct 21, 2026

Prevalence of Obstructive Sleep Apnea in HHT and HHT-specific Challenges in OSA-therapy - a Retrospective Cohort Study

View original source

Why it matters

Understanding the prevalence and implications of OSA in HHT patients is critical as it may influence treatment strategies and improve patient outcomes, particularly given the challenges associated with standard therapies.

Objective

To determine the frequency of obstructive sleep apnea (OSA) diagnoses in patients with hereditary hemorrhagic telangiectasia (HHT).

Results

Preliminary analysis indicated a significant presence of OSA in the HHT cohort, with associated challenges in treatment due to the unique vascular complications presented by HHT.

Methods

A retrospective cohort study was conducted, analyzing clinical records of HHT patients for documented OSA diagnoses and related complications. Secondary endpoints included OSA diagnostics, treatment course, comorbidities, and effects of therapy.

Limitations

The study is limited by its retrospective nature, with the potential underreporting of OSA due to lack of systematic screening in all patients. Therefore, results may not reflect the true prevalence of OSA in the HHT population.

For your doctor:

ClinicalTrials.gov: NCT07886632

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder (prevalence approx. 1:5,000-1:8,000) characterized by recurrent epistaxis, mucocutaneous telangiectasias and visceral vascular malformations. Chronic bleeding frequently leads to anemia and iron deficiency, which is associated with restless legs syndrome. Our earlier work suggested that up to 22% of affected patients may suffer from it. Nocturnal epistaxis, nasal clots, and nasal obstruction may further disturb sleep, and positive airway pressure (PAP) therapy may dry out the nasal mucosa, aggravate bleeding, and cause mask intolerance. The association between obstructive sleep apnea (OSA) and HHT has not yet been adequately studied. This retrospective, exploratory, hypothesis-generating analysis aims to determine the frequency of OSA diagnoses documented in the clinical records of our existing HHT cohort. The primary endpoint is this documented frequency, explicitly interpreted as a minimum frequency rather than a true prevalence, since not all patients were systematically screened. Secondary endpoints include details of OSA diagnostics and treatment course, complications of OSA therapy in HHT patients, OSA-related comorbidities (e.g., arterial hypertension, obesity), medication and potential adverse effects (especially respiratory depression), hypoxia-related laboratory parameters (iron status, anemia), and general patient and disease characteristics (sex, weight, height, Curaçao criteria). The findings are intended to inform a possible subsequent prospective screening phase.